Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 7000 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The stock has a 50-day moving average price of C$0.01 and a two-hundred day moving average price of C$0.01. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The stock has a market cap of C$663,150.00, a price-to-earnings ratio of -0.50 and a beta of -0.02.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Recommended Stories
- Five stocks we like better than Aequus Pharmaceuticals
- What is the Hang Seng index?
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- The Basics of Support and Resistance
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What is a Secondary Public Offering? What Investors Need to Know
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
